Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Context Therapeutics Inc

CNTX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.52

▲ +3.26%

Market Cap $48.04M · Vol 215.23K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$48.04M

Micro Cap

Div Yield

N/A

EPS Growth

-15.79%

YoY

RSI (14)

39.66

Momentum

Beta

1.70

vs Market

52W High

$3.62

85.56% below

52W Low

$0.43

20.26% above

Volume

215.23K

Avg 312.41K

P/B

2.23

Price-to-book

ROE

N/A

Return on equity

Free Float

98.42%

Public shares

Shariah Compliance8 STANDARDS

✗ Context Therapeutics Inc (CNTX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CNTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.04%

-16.05%

-77.56%

-77.27%

YTD

-64.43%

-28.98%

-56.06%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-36,123,620.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-43.36% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.23
P/FCF	N/A
EPS Growth	-15.79%
Outstanding Shares	91.88M

Technical Indicators

50-Day SMA	$0.74
200-Day SMA	$1.69
RSI (14)	39.66
Beta	1.70
52-Week High	$3.62
52-Week Low	$0.43

Volume Today	215.23K
Avg Daily Volume (30D)	312.41K
Relative Volume	0.69x
Volatility (10D)	177.48
Volatility (30D)	123.67
Free Float	98.42%

Analyst Consensus

BUY

Current Price $0.52

Mean Target $4.38

52W Low$0.43 52W High$3.62

Current

Target

$0.43 $3.62

Current Analyst target

+736.68% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG011YW6J46

ISINUS21077P1084

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.